Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating hypertensive left ventricular hypertrophy and application thereof

A technique for hypertension and composition, applied in the field of pharmaceutical compositions for treating hypertensive left ventricular hypertrophy, can solve the problems of no obvious curative effect and unsatisfactory effect in ventricular hypertrophy, and achieves increasing patient compliance, reducing dosage, increasing safety effect

Inactive Publication Date: 2014-06-11
南通海门凤成旅游文化发展有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although many antihypertensive drugs can effectively reduce the blood pressure of patients, they have no obvious effect on ventricular hypertrophy in hypertensive patients. Only a few antihypertensive drugs, such as angiotensin converting enzyme inhibitors, angiotensin Although receptor antagonists can reverse the ventricular hypertrophy of patients, the effect is not very satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The following are specific examples of the present invention, and further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these examples. All changes or equivalent substitutions that do not depart from the concept of the present invention are included in the protection scope of the present invention.

[0018] 14-week-old essential hypertensive rats (SHR), body weight 120±10g, half male and half male. A large number of research reports have confirmed that SHR rats have formed left ventricular hypertrophy at the age of 14 weeks. The 14-week-old SHR rats were divided into model control group, test group I, test group II and test group III, with 12 rats in each group. Twelve 14-week-old normal Wistar rats were used as the normal control group. See Table 1 for the specific dosage of the test substance. Administration once a day for 3 consecutive months.

[0019] Table 1 The test substance and d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating hypertensive left ventricular hypertrophy; the pharmaceutical composition comprises total glucosides of paeony and at least one angiotensin converting enzyme inhibitor; the angiotensin converting enzyme inhibitor is captopril, enalapril, perindopril or fosinopril. The pharmaceutical composition has very significant reverse effect on hypertension induced ventricular hypertrophy; by adopting the pharmaceutical composition, the perfect synergy function on each index such as left ventricular index of myocardial hypertrophy is obtained.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for treating hypertensive left ventricular hypertrophy. Background technique [0002] Hypertensive left ventricular hypertrophy refers to the increase in left ventricular weight due to hypertension, including hypertrophy of cardiomyocytes, hyperplasia of connective tissue, and increased cell volume without changing the number of cells. Left ventricular hypertrophy can undergo a series of changes in cell biochemistry, ultrastructure, myocardial energy metabolism, diastolic function and blood supply, and finally lead to deterioration of cardiac function. On the one hand, left ventricular hypertrophy is an adaptive hypertrophy of the heart, which is a compensatory mechanism; on the other hand, it is an independent risk factor for cardiovascular events. With the progression of hypertensive left ventricular hypertrophy, co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K36/71A61K38/05A61P9/12A61P9/00A61K31/401A61K31/675
Inventor 邵明凤
Owner 南通海门凤成旅游文化发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com